All Articles
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy. Read More ›
The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting. Read More ›
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients. Read More ›
Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. Read More ›
On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication. Read More ›
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer. Read More ›
Over the past several decades, we have seen the delivery of chemotherapy shift from the hospital inpatient setting to the hospital outpatient setting to the specialized community practice setting. Now, amid the many seismic changes that have been occurring as a result of the COVID-19 pandemic, a battle has emerged over the question of whether a patient’s home should be a site of care for the infusion of certain chemotherapy drugs. Read More ›
By Wayne Kuznar
The first “off-the-shelf” chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) who received treatment with the universal CAR T-cell therapy currently labeled GC027. Read More ›
Large community care centers remain committed to providing necessary treatments to patients with cancer during the COVID-19 pandemic. During a recent webcast titled Community Cancer Care Providers, which is part of the Association for Value-Based Cancer Care (AVBCC) webcast series: COVID-19 Impact on the Cancer Care Delivery Ecosystem, a panel of healthcare executives discussed how the pandemic is reshaping the ways in which community cancer centers provide care to their patients, the challenges that providers face as they navigate an evolving healthcare ecosystem, and how practices can continue to deliver care in the months ahead. Read More ›
By Wayne Kuznar
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Read More ›